Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy

Leukemia and Lymphoma

Volumn 52, Issue 10, 2011, Pages 1891-1897

  Morris, Patrick G ^a   Abrey, Lauren E ^a   Reiner, Anne S ^b   Wu, Nian ^a   Panageas, Katherine S ^b   Seko, Brian S ^a   Deangelis, Lisa M ^a   Omuro, Antonio ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Department of Epidemiology and Biostatistics ^*  (United States)

Author keywords

area under the curve; immunochemoradiotherapy; Methotrexate; primary CNS lymphoma; prognosis

Indexed keywords

FOLINIC ACID; METHOTREXATE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POST HOC ANALYSIS; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; WHOLE BODY RADIATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; CYTARABINE; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; METHOTREXATE; MIDDLE AGED; PROCARBAZINE; PROGNOSIS; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 80053199329     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.585527     Document Type: Article

References (19)

1. Morris PG, Abrey LE. Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 2009;8:581-592.
2. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-0. J Clin Oncol 2002;20: 4643-4648. (Pubitemid 36025280)
3. Vassal G, Valteau D, Bonnay M, Patte C, Aubier F, Lemerle J. Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin's lymphoma. Pediatr Hematol Oncol 1990;7:71-77. (Pubitemid 20078736)
4. Ferreri AJ, Guerra E, Regazzi M, et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 2004;90: 353-358. (Pubitemid 38250628)
5. Joerger M, Huitema AD, Krahenbuhl S, et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokineticpharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010;102:673-677.
6. Blasco H, Senecal D, Le Gouge A, et al. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma. Br J Clin Pharmacol 2010;70:367-375.
7. Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007;25:4730-4735. (Pubitemid 350086474)
8. Mathijssen RH, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist 2007;12:913923.
9. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006;24: 5711-5715. (Pubitemid 46631313)
10. Batchelor T, Grossman SA, Carson K, J. F. Updated results of NABTT CNS consortium studies in primary CNS lymphoma. Ann Oncol 2005;16:v125.
11. Herrlinger U, Kuker W, Uhl M, et al. NOA-03 trial of highdose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 2005;57:843-847. (Pubitemid 40798622)
12. Pels H, Schmidt-Wolf IGH, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003;21:4489-4495. (Pubitemid 46594018)
13. Abrey LE. Hematology. Individualized methotrexate dosing in primaryCNSlymphoma. Nat Rev Clin Oncol 2010;7:306-307.
14. Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994;12:1443-1451. (Pubitemid 24206244)
15. Delepine N, Delepine G, Cornille H, Brion F, Arnaud P, Desbois JC. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res 1995;15:489-494.
16. Zelcer S, KellickM,Wexler LH, et al.Methotrexate levels and outcome in osteosarcoma. Pediatr Blood Cancer 2005;44: 638-642. (Pubitemid 40629214)
17. Hiraga S, Arita N, Ohnishi T, et al. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 1999;91:221-230.
18. Jonsson P, Hoglund P, Wiebe T, Schroder H, Seidel H, Skarby T. Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia. Anticancer Drugs 2007;18:941-948. (Pubitemid 47220713)
19. Blakeley JO, Olson J, Grossman SA, He X, Weingart J, Supko JG. Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. J Neurooncol 2009;91:51-58.